Citations

Clear

16280 citation(s) found for "Yu, David".

Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Aisen, Paul, Beckett, Laurel , Bennett, David A. , Craft, Suzanne , Fagan, Anne M. , Iwatsubo, Takeshi , Jack, Clifford R. , Kaye, Jeffrey , Montine, Thomas J. , Park, Denise C. , Reiman, Eric M. , Siemers, Eric , Stern, Yaakov , Yaffe, Kristine , Carrillo, María C. , Thies, Bill, Morrison‐Bogorad, Marcelle, Wagster, Molly V., Phelps, Creighton H., Sperling, Reisa Anne , Rowe, Christopher Cleon , Bennett, David A. , Jack, Clifford R , Stern, Yaakov

Mayo Clinic

Alzheimer's & Dementia | April 22, 2011 | Volume: 7 | Issue: 3 | Pages: 280-292

10.1016/j.jalz.2011.03.003 | PMID 21514248 Get It

The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.
Radiation Dose Reduction for CT-Guided Renal Tumor Cryoablation
Atwell, Thomas D. , Yu, Lifeng , Mandrekar, Jay , Lewis, Bradley, Woodrum, David A. , Leng, Shuai , Yu, Lifeng , McCollough, Cynthia H.

Mayo Clinic

American Journal of Roentgenology | April 21, 2011 | Volume: 196 | Issue: 5 | Pages: W586-W591

10.2214/ajr.10.5144 | PMID 21512049 Get It

Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists
Bahn, Rebecca S. , Burch, Henry B. , Cooper, David S. , Garber, Jeffrey R., Greenlee, M. Carol , Klein, Irwin, Laurberg, Peter, McDougall, I. Ross, Montori, Víctor M. , Rivkees, Scott A. , Ross, Douglas S. , Stan, Marius N. , Sosa, Julie Ann , Montori, Victor M , Stan, Marius N

Mayo Clinic

Thyroid | April 21, 2011 | Volume: 21 | Issue: 6 | Pages: 593-646

10.1089/thy.2010.0417 | PMID 21510801 Get It

Paramediastinal Air Cyst with Traumatic Bronchial Injury: A Rare Complication of Neonatal Resuscitation
Said, Sameh M. , Salhab, Khaled F., Muehlstedt, Steven G., Wahoff, David C.

Mayo Clinic

The Thoracic and Cardiovascular Surgeon | April 21, 2011 | Volume: 60 | Issue: 03 | Pages: 236-238

10.1055/s-0030-1270946 | PMID 21509722 Get It

Patient Outcomes With Endovascular Embolectomy Therapy for Acute Ischemic Stroke
Brinjikji, Waleed , Kallmes, David F. , Cloft, Harry J. , Rabinstein, Alejandro A.

Mayo Clinic

Stroke | April 15, 2011 | Volume: 42 | Issue: 6 | Pages: 1648-1652

10.1161/strokeaha.110.607952 | PMID 21493901 Get It

Background and Purpose— Maturing techniques have spurred widespread implementation of endovascular embolectomy therapy for ischemic stroke. We evaluated a large administrative database to determine outcomes in patients treated with endovascular embolectomy in the general population. Methods— Using the National Inpatient Sample, we evaluated outcomes of patients treated for acute ischemic stroke in the United States from 2006 to 2008. Patients who had an ischemic stroke and underwent endovascular clot retrieval were identified. Morbidity, defined as “discharge to long-term facility,” and mortality were evaluated as a function of patient age and of concomitant thrombolytic agent administration. Results— For 2006 to 2008, a total of 3864 patients received endovascular clot retrieval with 266 (6.9%) patients in 2006, 800 (20.7) patients in 2007, and 2798 (72.4%) patients in 2008. The discharge to a long-term facility rate was 51.3% (1983 of 3864). The in-hospital mortality rate was 24.3% (940 of 3864). For patients <65 years old, the rate of in-hospital death was 17.1% (283 of 1658) as compared with a rate of 29.7% (656 of 2206) for patients ≥65 years old ( P <0.0001). The rate of discharge to a long-term facility was 47.6% (789 of 1658) for patients <65 years old and 54.1% (1193 of 2206) for patients ≥65 years old ( P <0.0001). The rate of intracranial hemorrhage was 15.5% without concomitant thrombolysis and 20.0% with concomitant thrombolysis ( P =0.0009). Conclusions— Rates of morbidity and mortality remain high for patients with acute stroke, even in the setting of endovascular embolectomy. Advanced age portends a worse outcome and patients treated with concomitant use of thrombolytic agent had higher rates of intracranial hemorrhage than those without such therapy.
Application of Computer Modeling in Systemic VAD Support of Failing Fontan Physiology
Durham, Lucian A. , Burkhart, Harold M. , Joyce, Lyle D., Cetta, Frank , Phillips, Sabrina D. , Sundareswaran, Kartik S., Farrar, David J. , Park, Soon J., Dearani, Joseph A. , Cabalka, Allison K.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | April 13, 2011 | Volume: 2 | Issue: 2 | Pages: 243-248

10.1177/2150135110397386 | PMID 23804979 Get It

Although the Fontan procedure has been enormously successful in palliation of single-ventricle patients, many seem to experience progressive failure of the Fontan circulation over time. Ventricular assist devices (VADs) have developed into stable platforms for long-term support of adult patients with heart failure. Given the success of axial flow devices, it was hypothesized that the technology could provide clinical benefit to failing Fontan patients. The aim of this study was to use a computer model to evaluate VAD support in failing Fontan physiology. A computer model of Fontan circulation with heart failure was developed and the HeartMate II (HM II) (Thoratec Corp) axial flow ventricular assist device was connected to this model in a systemic configuration to examine its impact. Cardiac catheterization data from 7 patients (8 catheterization studies) with failing Fontan physiology were applied to this model to evaluate the impact of using the HM II in this manner. When the HM II was used in a systemic configuration at 8000 rpm, there was a 35% decrease in the systemic venous pressure in the Fontan circuit and a 63% decrease in pulmonary capillary wedge pressure with a resultant 41% increase in CI. The model also predicted patient-specific parameters where the VAD may not benefit the patient, such as fixed elevated pulmonary vascular resistance, low systemic ventricular end-diastolic pressure, and high unresponsive systemic vascular resistance. These data suggest a potential benefit from application of axial flow VAD technology in the management of failing Fontan physiology. Clinical correlation will allow for refinement of this model as a predictive tool in discerning which patients may benefit from placement of a VAD and what issues must be addressed prior to implanting the device.
Robot-Assisted Laparoscopic Reconstruction of Retrocaval Ureter: Description and Video of Technique
Leroy, Timothy J., Thiel, David D. , Igel, Todd C.

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | April 12, 2011 | Volume: 21 | Issue: 4 | Pages: 349-351

10.1089/lap.2010.0287 | PMID 21486152 Get It

Major Basic Protein from Eosinophils and Myeloperoxidase from Neutrophils Are Required for Protective Immunity to Strongyloides stercoralis in Mice
O’Connell, Amy E. , Hess, Jessica A., Santiago, Gilberto A. , Nolan, Thomas J. , Lok, James B. , Lee, James J. , Abraham, David , O'Connell, Amy E

Mayo Clinic

Infection and Immunity | April 12, 2011 | Volume: 79 | Issue: 7 | Pages: 2770-2778

10.1128/iai.00931-10 | PMID 21482685 Get It

ABSTRACTEosinophils and neutrophils contribute to larval killing during the primary immune response, and neutrophils are effector cells in the secondary response toStrongyloides stercoralisin mice. The objective of this study was to determine the molecular mechanisms used by eosinophils and neutrophils to control infections withS. stercoralis. Using mice deficient in the eosinophil granule products major basic protein (MBP) and eosinophil peroxidase (EPO), it was determined that eosinophils kill the larvae through an MBP-dependent mechanism in the primary immune response if other effector cells are absent. InfectingPHILmice, which are eosinophil deficient, withS. stercoralisresulted in development of primary and secondary immune responses that were similar to those of wild-type mice, suggesting that eosinophils are not an absolute requirement for larval killing or development of secondary immunity. TreatingPHILmice with a neutrophil-depleting antibody resulted in a significant impairment in larval killing. Naïve and immunized mice with neutrophils deficient in myeloperoxidase (MPO) infected withS. stercoralishad significantly decreased larval killing. It was concluded that there is redundancy in the primary immune response, with eosinophils killing the larvae through an MBP-dependent mechanism and neutrophils killing the worms through an MPO-dependent mechanism. Eosinophils are not required for the development or function of secondary immunity, but MPO from neutrophils is required for protective secondary immunity.
Amyloidosis: Pathogenesis and New Therapeutic Options
Merlini, Giampaolo , Seldin, David C. , Gertz, Morie A. , Merlini, Giampaolo

Mayo Clinic

Journal of Clinical Oncology | April 12, 2011 | Volume: 29 | Issue: 14 | Pages: 1924-1933

10.1200/jco.2010.32.2271 | PMID 21483018 Get It

The systemic amyloidoses are a group of complex diseases caused by tissue deposition of misfolded proteins that results in progressive organ damage. The most common type, immunoglobulin light chain amyloidosis (AL), is caused by clonal plasma cells that produce misfolded light chains. The purpose of this review is to provide up-to-date information on diagnosis and treatment options for AL amyloidosis. Early, accurate diagnosis is the key to effective therapy, and unequivocal identification of the amyloidogenic protein may require advanced technologies and expertise. Prognosis is dominated by the extent of cardiac involvement, and cardiac staging directs the choice of therapy. Treatment for AL amyloidosis is highly individualized, determined on the basis of age, organ dysfunction, and regimen toxicities, and should be guided by biomarkers of hematologic and cardiac response. Alkylator-based chemotherapy is effective in almost two thirds of patients. Novel agents are also active, and trials are ongoing to establish their optimal use. Treatment algorithms will continue to be refined through controlled trials. Advances in basic research have led to the identification of new drug targets and therapeutic approaches, which will be integrated with chemotherapy in the future.
LIN28B Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer
Permuth‐Wey, Jennifer, Tsai, Ya-Yu, Lin, Hui‐Yi , Chen, Y. Ann , Barnholtz‐Sloan, Jill S. , Birrer, Michael J. , Bloom, Gregory, Chen, Zhihua , Cunningham, Julie M. , Dagne, Getachew , Ebbert-Syfrett, Judith, Fenstermacher, David, García‐Closas, Montserrat , Gayther, Simon A. , Bosquet, Jesús González , Goode, Ellen L. , Iversen, Edwin S., Kong, William, McLaughlin, John, Menon, Usha , Monteiro, Álvaro N.A. , Narod, Steven A., Phelan, Catherine M., Qu, Xiaotao , Ramus, Susan J. , Schildkraut, Joellen M. , Song, Honglin , Stockwell, Heather, Sutphen, Rebecca , Terry, Kathryn L. , Vierkant, Robert A. , Wentzensen, Nicolas , Lancaster, Johnathan M., Cheng, Jin Q. , Sellers, Thomas A. , Kim, Donghwa , Chanock, Stephen Jacob , Cramer, Daniel W. , Fridley, Brooke L. , Ge, William H. , Gentry‐Maharaj, Aleksandra , Jim, Heather , McLaughlin, John, Pharoah, Paul D.P. , Risch, Harvey A. , Tyrer, Jonathan P. , Ramus, Susan J , Vierkant, Robert A , Menon, Usha , Monteiro, Alvaro N , Barnholtz-Sloan, Jill S , Lin, Hui-Yi , García-Closas, Montserrat , Bosquet, Jesus Gonzalez

Mayo Clinic

Cancer Research | April 12, 2011 | Volume: 71 | Issue: 11 | Pages: 3896-3903

10.1158/0008-5472.can-10-4167 | PMID 21482675 Get It

Abstract Defective microRNA (miRNA) biogenesis contributes to the development and progression of epithelial ovarian cancer (EOC). In this study, we examined the hypothesis that single nucleotide polymorphisms (SNP) in miRNA biogenesis genes may influence EOC risk. In an initial investigation, 318 SNPs in 18 genes were evaluated among 1,815 EOC cases and 1,900 controls, followed up by a replicative joint meta-analysis of data from an additional 2,172 cases and 3,052 controls. Of 23 SNPs from 9 genes associated with risk (empirical P &lt; 0.05) in the initial investigation, the meta-analysis replicated 6 SNPs from the DROSHA, FMR1, LIN28, and LIN28B genes, including rs12194974 (G&gt;A), an SNP in a putative transcription factor binding site in the LIN28B promoter region (summary OR = 0.90, 95% CI: 0.82–0.98; P = 0.015) which has been recently implicated in age of menarche and other phenotypes. Consistent with reports that LIN28B overexpression in EOC contributes to tumorigenesis by repressing tumor suppressor let-7 expression, we provide data from luciferase reporter assays and quantitative RT-PCR to suggest that the inverse association among rs12194974 A allele carriers may be because of reduced LIN28B expression. Our findings suggest that variants in LIN28B and possibly other miRNA biogenesis genes may influence EOC susceptibility. Cancer Res; 71(11); 3896–903. ©2011 AACR.